Scilex Holding (SCLX) Cash from Financing Activities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Cash from Financing Activities of $9.1 million for Q1 2026, up 396.5% year-over-year from $1.8 million in Q1 2025, and down 47.81% on a QoQ basis from $17.5 million in Q4 2025.
Scilex Holding (SCLX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Cash from Financing Activities for 7 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 396.5% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $6.8 million (up 167.54% YoY), while the FY2025 annual figure was -$5.5 million, up 69.88% from the prior year.
- Cash from Financing Activities came in at $9.1 million for Q1 2026 at Scilex Holding, down from $17.5 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $43.5 million in Q2 2023, with the low at -$38.9 million in Q3 2023.
- Average Cash from Financing Activities over 5 years is $1.8 million, with a median of -$3.1 million recorded in 2025.
- The largest YoY upside for Cash from Financing Activities was 1849.77% in 2023 against a maximum downside of 466.26% in 2023.
- Year by year, Cash from Financing Activities stood at $426000.0 in 2022, then jumped by 1849.77% to $8.3 million in 2023, then sank by 186.48% to -$7.2 million in 2024, then soared by 343.91% to $17.5 million in 2025, then plunged by 47.81% to $9.1 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $9.1 million, $17.5 million, and -$11.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -3.47 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 530.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 919.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 267.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 9.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.14 Mn |
| Mar 31, 2026 | 9.14 Mn |
| Dec 31, 2025 | 17.52 Mn |
| Dec 31, 2025 | 17.52 Mn |
| Sep 30, 2025 | -11.30 Mn |
| Sep 30, 2025 | -11.30 Mn |
| Jun 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -8.60 Mn |
| Mar 31, 2025 | -3.08 Mn |
| Mar 31, 2025 | -3.08 Mn |
| Dec 31, 2024 | -7.18 Mn |
| Dec 31, 2024 | -7.18 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Mar 31, 2024 | -11.20 Mn |
| Mar 31, 2024 | -11.20 Mn |
| Dec 31, 2023 | 8.31 Mn |
| Dec 31, 2023 | 8.31 Mn |